ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR
(Thomson Reuters ONE) -
Press release
Murine form of THR-317 able to reduce inflammation, vascular leakage and
fibrosis
in the mouse eye, without triggering a neurodegenerative response.
Leuven, Belgium, 9(th) October 2017 - ThromboGenics NV (Euronext Brussels: THR),
a biotechnology company developing novel treatments for retinal disorders, with
a focus on diabetic eye disease, today announced that preclinical data on its
THR-317 have been published in Experimental Eye Research.
Experimental Eye Research peer-reviewed ThromboGenics' pre-clinical studies
designed to investigate inhibition of placental growth factor (PlGF) as a
possible therapy for Diabetic Retinopathy (DR). The effect of the murine form of
THR-317 was evaluated in various animal models by studying different DR disease
hallmarks, including vascular leakage, inflammation, neurodegeneration, and
fibrosis.
In its overall conclusion, the authors confirm that the anti-PlGF antibody
shared a common pharmacology towards vascular leakage in comparison to VEGF
inhibitors which are currently the standard of care for DR. Anti-PlGF therapy
might provide additional benefits in respect to the reduction of inflammation,
the absence of a negative impact on the neuroretina, and the inhibition of
fibrotic responses after retinal damage, as such supporting its therapeutic
potential for treating DR.
The article 'Neutralization of placental growth factor as a novel treatment
option in diabetic retinopathy' can be consulted online here.
Patrik De Haes, MD, CEO of ThromboGenics nv, said "We are pleased that our
cutting-edge research is being published in the prestigious Experimental Eye
Research journal. The published preclinical data show that, the murine form of
THR-317 is able to reduce vascular leakage, inflammation and fibrosis in the
mouse eye, without triggering a neurodegenerative response. The data further
validate the therapeutic potential of THR-317 for treating Diabetic
Retinopathy."
ThromboGenics is conducting a Phase I/IIa clinical study evaluating THR-317
(anti-PlGF) for Diabetic Macular Edema (DME). The trial was initiated in January
2017 and assesses THR-317's activity in subjects with DME. Study results are
expected during Q1 2018.
- END -
For further information please contact:
+----------------------------------------+-------------------------------------+
|ThromboGenics |Citigate Dewe Rogerson |
|Wouter Piepers, |David Dible/ Sylvie Berrebi/ Isabelle|
|Global Head of Corp Coms & Investor|Andrews |
|Relations |Tel: +44 20 7282 9571 |
|+32 16 75 13 10 / +32 478 33 56 32 |thrombogenics(at)citigatedr.co.uk |
|wouter.piepers(at)thrombogenics.com | |
| | |
+----------------------------------------+-------------------------------------+
About ThromboGenics
ThromboGenics is a biopharmaceutical company focused on developing innovative
treatments for eye disease, with a focus on diabetic eye disease. The company's
pipeline of disease modifying drug candidates is targeting the key segments of
the diabetic eye disease market.
ThromboGenics is conducting a Phase IIa clinical trial evaluating multiple doses
of THR-409 (ocriplasmin) to induce a total Posterior Vitreous Detachment in
patients with Non-Proliferative Diabetic Retinopathy (NPDR).
ThromboGenics is conducting a Phase I/IIa clinical study evaluating THR- 317, a
PlGF inhibitor for the treatment of diabetic macular edema, as a stand-alone or
as a combination therapy with anti-VEGF treatments. In addition, THR-149, a
plasma kallikrein inhibitor, which has resulted from research collaboration with
Bicycle Therapeutics, and THR-687, an integrin antagonist, which was in-licensed
from Galapagos, are in late stage pre-clinical development.
ThromboGenics pioneered a new drug category of pharmacological vitreolysis with
JETREA® (ocriplasmin) which is now approved for the treatment of symptomatic
vitreomacular traction in 54 countries worldwide.
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE
Euronext Brussels exchange under the symbol THR. More information is available
at www.thrombogenics.com
Important information about forward-looking statements
Certain statements in this press release may be considered "forward-looking".
Such forward-looking statements are based on current expectations, and,
accordingly, entail and are influenced by various risks and uncertainties. The
Company therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume an obligation to update or
revise any forward-looking statement, whether as a result of new information,
future events or any other reason. Additional information concerning risks and
uncertainties affecting the business and other factors that could cause actual
results to differ materially from any forward-looking statement is contained in
the Company's Annual Report.
This press release does not constitute an offer or invitation for the sale or
purchase of securities or assets of ThromboGenics in any jurisdiction. No
securities of ThromboGenics may be offered or sold within the United States
without registration under the U.S. Securities Act of 1933, as amended, or in
compliance with an exemption therefrom, and in accordance with any applicable
U.S. state securities laws.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ThromboGenics NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Marapharm Ventures Inc. is building a third facility in Las Vegas, Nevada, of 65,625 square feetDatum: 09.10.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 562821
Anzahl Zeichen: 6877
contact information:
Town:
Leuven
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 257 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ThromboGenics announces publication in Experimental Eye Research of preclinical data supporting therapeutic potential of THR-317 in DR"
steht unter der journalistisch-redaktionellen Verantwortung von
ThromboGenics NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
